36 Krypton learned that Xinsu Technology, a new company in the field of DNA synthesis, announced that it has completed an angel round of financing of tens of millions of yuan. This round of financing was led by Fengrui Capital, and Jiacheng Capital followed the investment.
“Synthetic biology” is considered to be about to promote the “third biotechnology revolution” and is the incubator of the next 100 billion dollar industry. This frontier discipline has emerged since the beginning of the 21st century. On the basis of systems biology, it combines engineering ideas with new technologies such as genome sequencing, computer simulation, and chemical synthesis technology. The goal of artificial life has promoted the transition of life science from interpreting life to compiling life.
In China, start-up companies capable of setting foot in the DNA synthesis industry are rare; in the world, the second- and third-generation DNA synthesis technologies are mainly mastered by overseas companies such as TWIST. Founded in 2021, Xinsu Technology applies semiconductor technology to synthetic biology, with the goal of three generations of DNA synthesis technology.
Xin Su Technology CEO Dr. Zhao Xin said: “DNA synthesis technology is at the top of the biological industry, and its future application scenarios are extremely wide. It can be applied to many fields such as synthetic biology, DNA storage, antibody drug screening, etc. The DNA synthesis radiation exceeds 100 billion U.S. dollars market. On the other hand, the rapid development of immunoassays, clinical diagnosis and scientific research have put forward higher requirements for the sensitivity of immunoassays, such as ELISA, which has been increased by 1,000 times. It can be seen that both the DNA synthesis market and the immunoassay market are both It has a huge potential for expansion. However, the existing DNA synthesis technology is far unable to meet the low-cost, high-throughput and high quasi accuracy requirements. “
The common international challenge is to reduce the cost of long-strand DNA synthesis. Faced with this problem, Xinsu Technology’s solution is to use silicon chips and microfluidics to develop a new generation of DNA synthesis technology. The inherent miniaturization and high integration characteristics of silicon chips and microfluidics can provide ultra-high throughput and ultra-high integration. Sensitivity, which will greatly reduce the cost of long-strand DNA synthesis to meet the rapid development of synthetic biology and DNA storage.
At the same time, using the same technology platform, Xinsu Technology is also developing a digital immunoassay system with a sensitivity of 2 to 3 orders of magnitude higher than that of traditional detection methods to meet the requirements for the detection of low-abundance protein markers in clinical and life science research.
“The company is currently in the R&D stage and will establish cooperation with scientific research institutes and companies. There are two cooperation modes: CRO mode is adopted for large-scale customers, and printers are sold for small-scale customers.” Dr. Zhao Xin said: “Printer equipment It is the fastest model to increase sales. Many second-generation DNA synthesis technologies cannot be used as printers. Xinsu Technology can cross this threshold. This is also our important advantage.”
Feng Rui Capital’s founding partner, Li Feng, said: “Chip and medical are the two hottest fields now, as well as the two fields where innovation is concentrated. At the intersection of these two fields, young scientists from MIT will explore synthetic biology. We are very optimistic about the application of science and single molecule detection.”
The founding team members of Xin Su Technology are all PhDs from MIT, and they have accumulated more than ten years of research and development in semiconductors, microfluidics and biotechnology. Co-founder Zhao Xin graduated from the School of Physics of Peking University with the first prize , and then studied for a doctorate at MIT, engaged in semiconductor process and device research, and was selected into the national talent program. Zhao Xin designed and prepared the world’s smallest and highest transconductance vertical structure field effect transistor (MOSFET) for the first time in the world, and was selected by the 2017 International Components and System Blueprint as the most ideal field effect transistor in the industry in the next 20 years. , Is one of the most powerful competitors for the next generation of integrated circuit components. The device technology has published more than 40 papers (Google Scholar cited more than 700 times), and its work has been followed up by many of the world’s top scientific research groups (Eli Yablonovitch, Academician of the Fourth American Academy of Sciences, etc.) and highly praised ( Academician Huang Ru and Academician Hao Yue, Chinese Academy of Sciences, etc.) , Its semiconductor device research results have been adopted by leading international semiconductor companies including TSMC , IBM, IMEC, Sematech, Lam Research and Oxford Instruments, etc., verifying the entire process of transforming innovative technologies into products and gradually landing in the industry. Co-founder Wu Dan graduated from the Department of Mechanical Engineering of MIT. He has more than 10 years of scientific research and industrial experience in ultrasound imaging, biochemistry, cell manipulation and microfluidics technology. He independently developed a high-throughput and high-sensitivity test for sepsis. The POC immune detection platform, which is used by Novartis Biomedical Research Center to monitor the cytokine release syndrome of CAR-TTherapy patients. In 2021, Zhao Xin and Wu Dan returned to China from the United States to co-found Xinsu Technology.
Li Li, founding partner of Jiacheng Capital, said: “Synthetic DNA is the foundation of synthetic biology. Chip-based high-throughput synthesis is very difficult, and the team needs a strong interdisciplinary background.”
It is understood that Xinsu Technology is about to launch a new round of financing, with a target financing amount of 50-60 million yuan, and it is inclined to focus on investment institutions that focus on medical or deep technology .
Global investment in synthetic biology from 2016 to 2019, source: Synbiobeta
In recent years, global capital markets have gradually shown their preference for the synthetic biology industry. Synbiobeta According to statistics, the first half of 2019, global 65 synthetic biology related companies to raise capital Jinda $ 1.9 billion of funds, the industry developed very rapidly. On the track, domestic pioneering companies also include Diying Biology and Kyanite Microbes .
Ma Rui, Executive Director of Fengrui Capital, said: “As a new smart infrastructure, chip + microfluidics can often provide real high-throughput, ultra-high-sensitivity detection capabilities and highly integrated lightweight hardware for biological scenarios. The founding team are all PhDs from MIT. They have many years of industrial experience and deep technical accumulation in the design and manufacturing of biochips , sensors, microfluidic systems, MEMS, etc.. I am very optimistic about the company’s use of new biochips and semiconductor technologies in synthetic biology The field explores the application of high-throughput DNA synthesis and the implementation of single-molecule detection of proteins in the field of digital immunity.
Posted by:CoinYuppie，Reprinted with attribution to:https://coinyuppie.com/focus-on-the-intersection-of-semiconductor-and-medical-technology-xinsu-technology-received-tens-of-millions-of-angel-round-investment/
Coinyuppie is an open information publishing platform, all information provided is not related to the views and positions of coinyuppie, and does not constitute any investment and financial advice. Users are expected to carefully screen and prevent risks.